-+ 0.00%
-+ 0.00%
-+ 0.00%

Hong Kong stock changes|Pharmaceutical Juno-B (02126) fell by more than 9%, and the price of CAR-T drugs was reduced by one million, and the medical insurance plan was to discount 2.97% of the shares and raise HK$160 million

Zhitongcaijing·11/17/2026 06:57:02
Listen to the news

The Zhitong Finance App learned that the decline in Yao Ming Junuo-B (02126) increased by more than 9% in the afternoon. The company's stock price was on a “roller coaster” yesterday. After opening nearly 15% higher in early trading, it quickly retreated, and eventually closed down more than 7%. As of press release, it decreased by 9.62% to HK$2.255, with a turnover of HK$4.299,000.

According to the news, on November 14, the National Health Insurance Administration released the 2026 “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue”. Pharmaceutical Junuo's CAR-T drug Benodat® (Rekiolense Injection) was included, making it the first and currently the only CAR-T drug to enter the national basic medical insurance catalogue. Before entering medical insurance, the price was 1.29 million yuan/branch. According to Yao Ming Junuo, from January 1, 2027, Benoda®'s medical insurance payment standard will be 288,600 yuan, and the production cost will be more than 500,000 yuan.

Furthermore, on the evening of November 15, Yao Ming Junuo announced that it would issue 61.185,500 shares to the two subscribers, accounting for 12.8% of the expanded share capital, with a subscription price of HK$2,615 per share, discounted 2.97% from the closing price of HK$2,695 on November 13, and raised HK$160 million, with a net amount of HK$158.8 million. The company plans to use 40% to promote R&D activities related to internal CAR-T product pipelines, another 30% for in-house CAR-T product pipeline R&D, clinical research, process optimization, etc., and the remaining 20% will be used for continuous development and upgrading of technology platforms and manufacturing capabilities, and about 10% for working capital.